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Abstract
Introduction: Mammographic density is well-established as a risk factor for breast cancer, however, adjustment for
age and body mass index (BMI) is vital to its clinical interpretation when assessing individual risk. In this paper we
develop a model to adjust mammographic density for age and BMI and show how this adjusted mammographic
density measure might be used with existing risk prediction models to identify high-risk women more precisely.
Methods: We explored the association between age, BMI, visually assessed percent dense area and breast cancer
risk in a nested case-control study of women from the placebo arm of the International Breast Cancer Intervention
Study I (72 cases, 486 controls). Linear regression was used to adjust mammographic density for age and BMI. This
adjusted measure was evaluated in a multivariable logistic regression model that included the Tyrer-Cuzick (TC) risk
score, which is based on classical breast cancer risk factors.
Results: Percent dense area adjusted for age and BMI (the density residual) was a stronger measure of breast
cancer risk than unadjusted percent dense area (odds ratio per standard deviation 1.55 versus 1.38; area under the
curve (AUC) 0.62 versus 0.59). Furthermore, in this population at increased risk of breast cancer, the density residual
added information beyond that obtained from the TC model alone, with the AUC for the model containing both
TC risk and density residual being 0.62 compared to 0.51 for the model containing TC risk alone (P =0.002).
Approximately 16% of controls and 19% of cases moved into the highest risk group (8% or more absolute risk of
developing breast cancer within 10 years) when the density residual was taken into account. The net reclassification
index was +15.7%.
Conclusions: In women at high risk of breast cancer, adjusting percent mammographic density for age and BMI
provides additional predictive information to the TC risk score, which already incorporates BMI, age, family history
and other classic breast cancer risk factors. Furthermore, simple selection criteria can be developed using
mammographic density, age and BMI to identify women at increased risk in a clinical setting.
Clinical trial registration number: http://www.controlled-trials.com/ISRCTN91879928 (Registered: 1 June 2006).
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Introduction
Mammographic density is well-established as a risk fac-
tor for breast cancer [1]. Nevertheless, it is not yet
widely used to assess breast cancer risk because the
established methods of density assessment are not viable
for use in large numbers of mammograms, for example,
within a national screening programme. A number of
fully automated methods have been developed however,
which, once validated, are likely to allow large numbers
of mammograms to be rapidly and reliably measured for
density. A key question, therefore, is ‘how can we use
this information to identify and inform women at great-
est risk of developing breast cancer, so that we may offer
them risk-reducing interventions?’
Aside from the challenges involved in measuring
mammographic density, the issue of how to utilise mam-
mographic density information to estimate breast cancer
risk is also complicated by the fact that there is con-
founding between percent mammographic density, body
mass index (BMI) [2] and age [3], and possibly other
breast cancer risk factors as well. Thus, to assess a
woman’s risk of developing breast cancer from her mam-
mographic density, one must take into account her age
and BMI [4]. This means that we need a more nuanced
approach than using a fixed cut-off of, say, 50% dense.
Furthermore, it is not only the dense tissue itself
that confers the breast cancer risk. Body fat synthesises
and releases estrogens, particularly in postmenopausal
women, so that increased BMI is associated with in-
creased breast cancer risk in postmenopausal women
[2]. Currently, a woman’s risk of developing breast can-
cer can be assessed using one of a number of established
statistical models, but there has been little validation in
the general population [5-7]. Furthermore, attempts to
extend existing models to include mammographic dens-
ity have so far been disappointing. The incorporation of
mammographic density measured by Breast Imaging
Reporting and Data System (BI-RADS) categories into
the Gail model by Tice et al. [8] improved the predictive
power minimally. The addition of mammographic dens-
ity to the Breast Cancer Surveillance Consortium
(BCSC) [9], Barlow [10] and Gail [11] models led to only
modest improvements in discriminatory power. Never-
theless, in many health care systems access to breast
cancer risk-reducing interventions is contingent upon
having a high breast cancer risk as assessed by one of
these models. It is vital, therefore, to further develop
these models to incorporate mammographic density so
that when we are making such, sometimes life changing,
decisions we are taking into account all available infor-
mation. In this study, we use data on a subset of women
from the placebo arm of the International Breast Cancer
Intervention Study 1 (IBIS-1) [12,13] to develop a model
to adjust mammographic density (percent dense area)
for age and BMI and show how this adjusted mammo-
graphic density measure might be used with existing risk
prediction models to identify high-risk women more
precisely.
Materials and methods
The subjects of this study are 558 women from the pla-
cebo arm of the IBIS-I, a randomized trial of tamoxifen
versus placebo in women at high risk of developing breast
cancer. The IBIS-I trial is registered with controlled-trials.
com as ISRCTN91879928, which has been reported in full
elsewhere [12,13]. The selection process for this particular
subset was described in detail in the report of the IBIS-I
density case-control study [14]. There was no matching.
Briefly, women were eligible to participate in IBIS-I if they
were aged 35 to 70 years and breast cancer free but with
their risk of developing the disease estimated to be at least
twice the population average. At entry to the study,
women were randomised to take either tamoxifen (20 mg
daily) or placebo for five years, with six-monthly follow-up
appointments. Additionally, mammograms were required
at entry to the study and recommended at 12- to 18-
month intervals during the treatment period.
Written informed consent to participate in the study
and allow access to medical records was obtained from
all participants in IBIS-I prior to entry. Further written
consent for their mammograms to be used was obtained
subsequently. Both IBIS-I and the mammography study
were approved by North Somerset and South Bristol Re-
search Ethics Committee. For the IBIS-I density case-
control study the mammograms relating to 942 controls
(women without breast cancer) and 123 cases (British
and Finnish participants diagnosed with breast cancer
prior to 1 October 2007) were retrieved from local cen-
tres and mammographic density (percent dense area)
measured centrally by RW (a consultant radiologist).
Film mammograms of the left and right mediolateral ob-
lique views were placed together on the light-box and
read as a single entity. Percent dense area was assessed
visually to the nearest 5%.
Only participants from the placebo arm of the IBIS-I
density study (72 cases, 486 controls) were used in this
study as tamoxifen itself has a major impact on both
mammographic density and breast cancer development.
The majority of cases (64/72) were invasive. Median
follow-up for controls was 11.6 years. Median time to
diagnosis for cases was 5.1 years.
Statistical methods
Logistic regression (with breast cancer status as the
dependent variable and age, baseline percent dense area
and BMI as independent variables) was used to evaluate
the association between breast cancer risk and age, BMI
and percent dense area.
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Linear regression, fitted by ordinary least squares with
percent dense area at baseline as the dependent variable
and age and BMI as independent variables, was used to
adjust percent dense area for age and BMI. The trans-
formation d = log(z/(1-z)), where z = [0.025 + 0.95{x-min
(x)}/max(x)]1/2 and x = percent dense area, was used to
ensure that the residuals followed an (approximately)
normal distribution. Age and BMI were centred for
interpretability. Adjusted percent dense area (density
residual) was calculated as the difference between the
observed percent dense area (after transformation) and
the fitted value. Density residuals were standardised
to have mean 0 and variance 1. To be certain that all
relevant breast cancer risk factors had been included
in the density adjustment, we also investigated the effect
of adding age at menarche, parity, menopausal status,
previous biopsy, hormone replacement therapy, and
atypical hyperplasia or/and lobular carcinoma in situ to
the model.
In order to explore the additional effect on estimates
of breast cancer risk of adding density residual to a
breast cancer risk assessment model based on standard
breast cancer risks factors, we fitted a logistic regression
model with density residual and absolute risk of develop-
ing breast cancer within 10 years (as computed by the
Tyrer-Cuzick (TC) model [15]) as independent variables
and breast cancer status as the dependent variable. The
Tyrer-Cuzick model incorporates familial and personal
risk factors (including those listed above) but does not
so far include mammographic density. For comparison,
we also fitted a univariate logistic regression model with
unadjusted percent dense area as the independent vari-
able. Likelihood ratio tests were used to assess whether
the addition of each variable improved discrimination
[16]. All P values were two-sided.
For each subject the absolute risk of developing breast
cancer within the next 10 years (<3%, 3 to 5%, 5 to 8%,
8 +%) was calculated first from the TC model then modi-
fied to reflect the effect of mammographic density (by
multiplying the TC risk by the predicted odds ratio from
the logistic regression model containing only the density
residual or only the unadjusted density). The net reclas-
sification index for the TC model compared to TC plus
density residual, and for the TC model compared to
TC plus unadjusted density, was calculated and re-
classification tables presented [17].
Agreement between density readings obtained at dif-
ferent time points, or by different readers, was assessed
using Lin’s concordance correlation coefficient [18,19].
Results
The number of cases and controls, the total years
follow-up and baseline characteristics of the study group
are shown in Table 1. Median follow-up for controls was
11.6 years. Median time to diagnosis for cases was
5.1 years. The TC risk score (absolute risk of developing
breast cancer within the next 10 years) for our study
group varied from 1.6% to 34.2% with mean 6.0% (me-
dian 5.5%). Median percent dense area was 42.5% in
controls (interquartile range (IQR) 15.0 to 70.0) and
62.5% (IQR 25.0 to 80.0) in cases. BMI was missing for
six control women, age at menarche for four women
(two controls and two cases) and previous biopsy for
one control woman.
The reproducibility of the density readings was
assessed by having the images re-read by RW and an-
other trained reader (JS) 10 years after the initial read-
ing. For the baseline mammograms the concordance
coefficient between the original and repeat readings by
the original reader (RW) was very high (0.88 95% confi-
dence interval (CI): 0.87 to 0.90) with an average differ-
ence between readings of −3.04. The concordance
coefficient between the original readings by RW and re-
peat readings by JS was also very high (0.88 95% CI: 0.87
Table 1 Baseline characteristics of the study group (72
breast cancer cases and 486 controls from the placebo
arm of IBIS-I)
Variable Controls Cases
(n =486) (n =72)
Follow-up (years)† 11.6 (10.7-12.3) 5.1 (3.1-7.9)
Age (years)† 49.5 (46.4-54.4) 49.9 (46.3-56.0)
BMI (kg/m2)† 25.8 (23.4-29.1) 26.2 (23.7-28.4)
Menopausal status
Pre/peri 261 (54%) 38 (53%)
Post 225 (46%) 34 (47%)
HRT use
Never 316 (65%) 46 (64%)
Current 108 (22%) 14 (19%)
Previous 62 (13%) 12 (17%)
Age at menarche (years)† 13 (12-14) 13 (12-14)
Age at first birth
Nulliparous 69 (14%) 12 (17%)
>29 years 55 (11%) 6 (8%)
26-29 years 98 (20%) 14 (19%)
21-25 years 178 (37%) 27 (38%)
<21 years 86 (18%) 13 (18%)
Tyrer-Cuzick risk score
10-year absolute risk (%)† 5.5 (4.5-6.7) 5.4 (4.1-6.9)
10 -year relative risk† 2.2 (1.8-2.7) 2.1 (1.7-2.9)
Mammographic density
Percent dense area (%)† 42.5 (15.0-70.0) 62.5 (25.0-80.0)
†Median (interquartile range). BMI, body mass index; HRT, hormone
replacement therapy.
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to 0.90) with an average difference between readings
of 4.42.
The odds ratios for risk of developing breast cancer
from the multivariate logistic regression model including
age, BMI and percent dense area were 1.33 (95% CI:
0.86 to 2.04, P =0.20) per 10-year change in age at entry
to IBIS-I, 1.05 (95% CI: 0.99 to 1.11, P =0.07) per one
unit of BMI (kg/m2), and 1.16 (95% CI: 1.06 to 1.27,
P =0.001) per 10% change in percent dense area.
Details of how the density residual, which ranged
from −2.74 to 2.79, was calculated are given in Appendix A.
The odds ratios, confidence intervals, area under
the receiver operating characteristic curve (AUC) and
associated P values from the univariate and multivariate
logistic regression models with absolute TC risk, un-
adjusted percent dense area and density residual as inde-
pendent variables and breast cancer status as the
dependent variable are reported in Table 2. The density
residual was a stronger measure of breast cancer risk
than unadjusted percent dense area (odds ratio per
standard deviation 1.55 vs. 1.38) with the AUC being
0.62 compared with 0.59. The density residual added
statistically significant information beyond that obtained
from the TC model alone (P =0.002). Unadjusted per-
cent dense area was not significant in a model that
already included the density residual.
The numbers reclassified (absolute risk of developing
breast cancer within the next 10 years 3%, 3 to 5%, 5 to
8%, 8 +%) when the TC risk score was modified using
the density residual are given in Table 3. The net reclas-
sification index is +15.7%. Approximately 16% of con-
trols (76/480) moved into the highest risk group (8 +%)
when the density residual was taken into account
and 4% (19/480) moved from the highest risk group to
a lower risk one. Amongst cases, the equivalent figures
were 19% (14/72) and 1% (1/72) respectively. For
comparison, the numbers reclassified when unadjusted
percent dense area is used to modify the TC risk score
rather than density residual are also presented in Table 4.
Approximately 33% of controls (157/480) moved from
the highest risk group (8 +%) to a lower risk group when
the density residual was used to modify TC risk rather
than percent dense area. Amongst cases, the equivalent
Table 2 Odds ratios (OR) and area under the curve (AUC)
from the logistic regression models including absolute
Tyrer-Cuzick (TC) risk score, unadjusted percent dense
area and density residual as independent variables
Model Odds ratio†
(95% CI)
AUC LR-CHI2 Δ χ2
(P value)a
Univariate
Absolute TC risk score 1.18 (10.99-1.39) 0.51 3.5 0.06
Unadjusted percent
dense area
1.83 (1.14-2.94) 0.59 6.5 0.01
Density residual 1.90 (1.31-2.77) 0.62 11.7 0.001
Multivariate
Absolute TC risk 1.12 (0.94-1.33) 3.5 0.06
Density residual 1.82 (1.25-2.67) 0.62 9.9 0.002
†Odds ratio is for the difference between the 75th and 25th percentiles of the
Tyrer-Cuzick (TC) 10-year absolute risk, unadjusted percent dense area and the
density residual; athis is the change in χ2 when the variable is added to
the model.
Table 3 Numbers reclassified (absolute risk of developing
breast cancer within the next 10 years 3%, 3 to 5%, 5 to
8%, 8 +%) for the Tyrer-Cuzick (TC) risk score compared
to Tyrer-Cuzick risk score modified using the density
residual
TC/TC +
density
residual
<3% 3-5% 5-8% 8%+ Total
Control
<3% 10 (67%) 4 (27%) 1 (7%) 0 (0%) 15 (3%)
3-5% 52 (30%) 65 (38%) 44 (26%) 10 (6%) 171 (36%)
5-8% 8 (3%) 68(29%) 92 (39%) 66 (28%) 234 (49%)
8 +% 0 (0%) 3 (5%) 16 (27%) 41 (68%) 60 (12%)
Total 70 (15%) 140 (29%) 153 (32%) 117 (24%) 480 (100%)
Case
<3% 2 (50%) 2 (50%) 0 (0%) 0 (0%) 4 (6%)
3-5% 5 (17%) 13 (43%) 7 (23%) 5 (17%) 30 (42%)
5-8% 0 (0%) 9 (39%) 5 (22%) 9 (39%) 23 (32%)
8 +% 0 (0%) 0 (0%) 1 (7%) 14 (93%) 15 (21%)
Total 7 (10%) 24 (33%) 13 (18%) 28 (39%) 72 (100%)
Table 4 Numbers reclassified (absolute risk of developing
breast cancer within the next 10 years 3%, 3 to 5%, 5 to
8%, 8 +%) for the Tyrer-Cuzick (TC) risk score modified
using percent dense area compared to the Tyrer-Cuzick
risk score modified using the density residual
TC + unadjusted
density/TC +
density residual
<3% 3-5% 5-8% 8%+ Total
Control
<3% 4 (100%) 0 (0%) 0 (0%) 0 (0%) 4 (1%)
3-5% 47 (89%) 6 (11%) 0 (0%) 0 (0%) 53 (11%)
5-8% 19 (13%) 105 (70%) 25 (17%) 0 (0%) 149 (31%)
8 +% 0 (0%) 29 (10%) 128 (47%) 117 (43%) 274 (57%)
Total 70 (15%) 140 (29%) 153 (32%) 117 (24%) 480 (100%)
Case
<3% 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
3-5% 6 (55%) 5 (45%) 0 (0%) 0 (0%) 11 (15%)
5-8% 1 (6%) 15 (83%) 2 (11%) 0 (0%) 18 (25%)
8 +% 0 (0%) 4 (9%) 11 (26%) 28 (65%) 43 (60%)
Total 7 (10%) 24 (33%) 13 (18%) 28 (39%) 72 (100%)
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figure was 21% (15/72) respectively. The net reclassifica-
tion index is 16.9%.
Discussion
We have shown that by adjusting percent dense area
for age and BMI a better measure of breast cancer risk
is obtained. This adjusted measure provided additional
predictive information when added to the TC risk esti-
mates calculated from classic breast cancer risk factors.
Our findings suggest that even within known high-risk
groups, prevention strategies might be better targeted
as, with the addition of information from the density
residual, the number of women identified as having
the highest breast cancer risk (>8%) increased from 14%
(75/552) to 26% (145/552) and the proportion of cases
arising in the highest risk group increased from 21%
(15/72) to 39% (28/72). We also found that a woman
with high density residual but low TC risk might have a
greater chance of developing breast cancer than a similar
woman with low density residual but high TC risk. Fur-
thermore, the density residual was better at modifying
TC risk than unadjusted percent dense area.
Our study has a number of limitations. First, our model
for adjusting percent dense area for age and BMI is based
on a relatively small number of women and therefore re-
quires validation. Second, since our subjects are from a
higher-risk population, our adjustment may not be appro-
priate for use in the general population. This may also ex-
plain the poor discrimination of the model containing TC
risk alone. Nevertheless, our results highlight the fact that
even among high-risk women the addition of mammo-
graphic density to existing breast cancer risk prediction
models seems likely to improve discrimination. The fur-
ther development and validation of these models should
therefore be a priority.
A weakness of previous attempts to incorporate infor-
mation on breast density into established risk prediction
models is that the only available measure of breast dens-
ity was categorical and therefore a less sensitive measure.
In our study group including breast density adjusted
for age and BMI improved the predictive ability of the
model. The model with TC risk and density residual had
almost four times as much information on breast cancer
risk as the TC risk alone (χ2 = 13.4 vs. 3.50). Therefore,
an important step will be to develop the TC model fur-
ther by incorporating an adjusted density measure into
the model. Further validation of these results in the Pre-
dicting Risk Of breast Cancer At Screening (PROCAS)
study [20] is planned as well as further analyses of the
relation between adjusted density and other classic risk
factors. Previous publications [8-10] on incorporation of
breast density into risk assessment models mainly used
BI-RADs categories. Chen et al. [11] used a continuous
measure of percent dense area coded into four categories,
while we used percent dense area assessed to the nearest
5%. Therefore, a standardised breast density reporting
must be achieved before breast density can be incorpo-
rated into a clinically useful risk assessment model [21].
Conclusions
We have found adjusting percent dense area for age and
BMI gives a stronger and more independent measure of
breast cancer risk. Adjusted density adds information to
a risk score from the TC model that already incorporates
BMI, age, family history and other risk factors. Further-
more, simple selection criteria can be developed using
mammographic density, age and BMI to identify women
at increased risk in a clinical setting.
Appendix A
Calculation of the density residual
Age, BMI, menopausal status, parity, age at menarche,
use of hormone replacement therapy, previous biopsy
and atypical hyperplasia or/and lobular carcinoma in situ
were considered for entry to the linear regression model
with transformed percent dense area (calculated as log(z/
(1 − z)), where z = [0.025 + 0.95{x −min(x)}/max(x)]1/2 and
x = percent dense area) as the dependent variable. The use
of hormone replacement therapy and age at menarche
was not significant. BMI explained around 15% of the
variation in transformed percent dense area, age ex-
plained 5%, parity explained 0.8%, menopausal status
0.6%, previous biopsy 1.8% and atypical hyperplasia or/
and lobular carcinoma in situ 1.3%. Compared with age
and BMI, the additional explanatory value of the other
risk factors was quite low so we decided not to include
them in the adjustment.
Adjusted percent dense area was calculated from the
following linear regression line
0:9208−0:1156 x BMI−26 kg=m2
 
– 0:0542 x Age−50 yrð Þ
Density residual was calculated as:
transformed percent dense area-adjusted percent dense
area.
To standardise, the density residual was divided by its
standard deviation (1.30).
Abbreviations
AUC: area under the receiver operating characteristic curve; BI-RADS: Breast
Imaging Reporting and Data System; BMI: body mass index; CI: confidence
interval; HRT: hormone replacement therapy; IBIS-I: International Breast
Cancer Intervention Study I; IQR: interquartile range; TC: Tyrer-Cuzick.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JW designed the study, analysed the data, interpreted the results and drafted
the paper. HB analysed the data, interpreted the results and drafted the
paper. JS designed the study, interpreted the results and reviewed the paper.
RMLW read the mammograms, interpreted the results and reviewed the
Warwick et al. Breast Cancer Research 2014, 16:451 Page 5 of 6
http://breast-cancer-research.com/content/16/5/451
paper. EP collected the mammograms and drafted the paper. ARB analysed
the data, interpreted the results and reviewed the paper. SWD designed the
study, interpreted the results and reviewed the paper. AH interpreted the
results and reviewed the paper. JC designed the study, interpreted the
results and drafted the paper. All authors read and approved the final
manuscript.
Acknowledgements
This work was supported by a Cancer Research UK programme grant (C569/
A10404 to J.C.) for research on the prevention of hormonally related cancers.
We wish to thank the IBIS investigators and local staff at participating centres
for their time and assistance in obtaining the mammograms for the study.
Author details
1Imperial Clinical Trials Unit, School of Public Health, Faculty of Medicine,
Imperial College London, St Mary’s Campus, Paddington, London, W2 1PG,
UK. 2Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine,
Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ,
UK. 3Centre for Genetic Origins of Health and Disease, University of Western
Australia, M40935 Stirling Highway, Perth, WA 6009, Australia. 4Cambridge
Breast Unit, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
5Genesis Breast Cancer Prevention Centre, University Hospital of South
Manchester, Southmoor Road, Manchester, M23 9QZ, UK.
Received: 20 November 2013 Accepted: 26 September 2014
References
1. McCormack VA, Dos Santos SI: Breast density and parenchymal patterns
as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol
Biomarkers Prev 2006, 15:1159–1169.
2. Boyd NF, Martin LJ, Sun L, Guo H, Chiarelli A, Hislop G, Yaffe M, Minkin S:
Body size, mammographic density, and breast cancer risk. Cancer
Epidemiol Biomarkers Prev 2006, 15:2086–2092.
3. Hutson SW, Cowen PN, Bird CC: Morphometric studies of age related
changes in normal human breast and their significance for evolution of
mammary cancer. J Clin Pathol 1985, 38:281–287.
4. Baglietto L, Krishnan K, Stone J, Apicella C, Southey MC, English DR, Hopper
JL, Giles GG: Associations of mammographic dense and nondense areas
and body mass index with risk of breast cancer. Am J Epidemiol 2014,
179:475–483.
5. Assi V, Warwick J, Cuzick J, Duffy SW: Clinical and epidemiological issues in
mammographic density. Nat Rev Clin Oncol 2012, 9:33–40.
6. Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB: Breast cancer
risk assessment across the risk continuum: genetic and nongenetic risk
factors contributing to differential model performance. Breast Cancer Res
2012, 14:R144.
7. Gail MH, Mai PL: Comparing breast cancer risk assessment models. J Natl
Cancer Inst 2010, 102:605–608.
8. Tice JA, Cummings SR, Ziv E, Kerlikowske K: Mammographic breast density
and the Gail model for breast cancer risk prediction in a screening
population. Breast Cancer Res Treat 2005, 94:115–122.
9. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske
K: Using clinical factors and mammographic density to estimate breast
cancer risk: development and validation of a new predictive model.
Ann Intern Med 2008, 148:337–347.
10. Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA,
Tice JA, Buist DS, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K:
Prospective breast cancer risk prediction model for women undergoing
screening mammography. J Natl Cancer Inst 2006, 98:1204–1214.
11. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail
MH: Projecting absolute invasive breast cancer risk in white women with
a model that includes mammographic density. J Natl Cancer Inst 2006,
98:1215–1226.
12. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A,
Howell A, Powles T, IBIS investigators: First results from the International
Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
Lancet 2002, 360:817–824.
13. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A,
International Breast Cancer Intervention Study (IBIS) I Investigators:
Long-term results of tamoxifen prophylaxis for breast cancer – 96-month
follow-up of the randomised IBIS-I trial. J Natl Cancer Inst 2007, 99:272–282.
14. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF,
Warren RM: Tamoxifen-induced reduction in mammographic density and
breast cancer risk reduction: a nested case–control study. J Natl Cancer
Inst 2011, 103:744–752.
15. Tyrer J, Duffy SW, Cuzick J: A breast cancer prediction model incorporating
familial and personal risk factors. Stat Med 2004, 23:1111–1130.
16. Pepe MS, Kerr KF, Longton G, Wang Z: Testing for improvement in
prediction model performance. Stat Med 2013, 32:1467–1482.
17. Pencina MJ, D’Agostino RB, Steyerberg EW: Extension of net
reclassification improvement calculations to measure usefulness of new
biomarkers. Stat Med 2011, 30:11–21.
18. Krippendorff K: Bivariate agreement coefficients for reliability of data.
In Sociological Methodology. Edited by Borgatta EF, Bohrnstedt GW. San
Francisco: Jossey-Bass; 1970:139–150.
19. Lin LI: A concordance correlation coefficient to evaluate reproducibility.
Biometrics 1989, 45:255–268.
20. Evans DG, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, McBurney H,
Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant JC,
Newman WG, Buchan I, Cuzick J, Howell A: Assessing individual breast
cancer risk within the U.K. National Health Service Breast Screening
Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila)
2012, 5:943–951.
21. Bondy ML, Newman LA: Assessing breast cancer risk: evolution of the
Gail Model. J Natl Cancer Inst 2006, 98:1172–1173.
doi:10.1186/s13058-014-0451-5
Cite this article as: Warwick et al.: Mammographic breast density refines
Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings
from the placebo arm of the International Breast Cancer Intervention
Study I. Breast Cancer Research 2014 16:451.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Warwick et al. Breast Cancer Research 2014, 16:451 Page 6 of 6
http://breast-cancer-research.com/content/16/5/451
